Effects of MAO inhibitors upon MPTP mice chronically treated with suprathreshold doses of L-dopa

Behavioural Pharmacology

Volumn 11, Issue 7-8, 2000, Pages 571-581

  Fredriksson, A ^a   Palomo, T ^a   Archer, T ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Amiflamine; C57 BL 6 mice; Clorgyline; DA depletion; Hypoactivity; L deprenyl; L dopa; MPTP; Phenelzine; Ro 41 1049; Synergistic restoration; Threshold dose; ethyltryptamine

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AMIFLAMINE; CLORGYLINE; DOPAMINE; ETRYPTAMINE; LEVODOPA; MONOAMINE OXIDASE A INHIBITOR; MONOAMINE OXIDASE B INHIBITOR; N (2 AMINOETHYL) 5 (3 FLUOROPHENYL) 4 THIAZOLECARBOXAMIDE; PHENELZINE; SELEGILINE; SODIUM CHLORIDE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MIXTURE; DRUG POTENTIATION; LOCOMOTION; MOTOR ACTIVITY; MOUSE; NONHUMAN;

EID: 0033636336     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008877-200011000-00004     Document Type: Article

References (49)

1. Increased total activity in the rat after L-tryptophan plus the monoamine oxidase-A inhibitor amiflamine but not after L-tryptophan plus clorgyline
2. Central noradrenaline depletion antagonizes aspects of D-amphetamine-induced hyperactivity in the rat
3. Deprenyl leads to prolongation of L-DOPA efficacy in Parkinson's disease
4. Pharmacology of the novel 5-hydroxytryptamine1A receptor antagonist (S)-5-fluoro-8-hydroxy-2-(dipropylamino)tetralin: Inhibition of (R)-8-hydroxy-2-(dipropylamino)tetralin-induced effects
5. Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 5,7-dihydroxytryptamine on the locomotor activity and striatal amines in C57B1/6 mice
6. Effects of MPTP on locomotor activity in mice
7. Effect of selective and reversible MAO inhibitors on dopamine outflow in rat striatum: A microdialysis study
8. Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase inhibitor type A
9. Motor function in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mouse
10. Behavioral effects of deprenyl in aged rats
11. Deprenyl (selegiline), a selective MAO-B inhibitor with active metabolites; Effects on locomotor activity, dopaminergic neurotransmission and firing rate of nigral dopamine neurons
12. Effect of L-deprenyl, its structural analogues and some monoamine oxidase inhibitors on dopamine uptake
13. Influence of selective inhibition of monoamine oxidase A or B on striatal metabolism of L-dopa in hemiparkinsonian rats
14. Selective monoamine oxidase inhibitors. 3. Cyclic compounds related to 4-aminophenethylamine. Preparation and neuron-selective action of some 5-(2-aminoethyl)-2,3-dihydroindoles
15. MPTP-induced behavioural and biochemical deficits: A paramatric analysis
16. Synergistic interactions between COMT-/MAO-inhibitors and L-dopa in MPTP-treated mice
17. MPTP-induced hypoactivity in mice: Reversal by L-dopa
18. Tolerance to a suprathreshold dose of L-dopa in MPTP mice: Effects of glutamate antagonists
19. Serotonergic functions in arousal and motor activity
20. Monoamine oxidase inhibition by the MAO-A inhibitors brofaromine and clorgyline in healthy volunteers
21. The role of the regulatory enzymes of catecholamine synthesis in Parkinson's disease
22. Inhibition by (-)deprenyl of dopamine uptake in the rat striatum: Possible correlation between dopamine uptake and acetylcholine release inhibition
23. Effect of monoamine oxidase A and B and of catechol-O-methyltransferase inhibition on L-dopa-induced circling behavior
24. Some features of the nigrostriatal dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse
25. A review of the pharmacology of selegiline
26. The pharmacology of selegiline [(-) deprenyl]. New aspects
27. Chronic parkinsonism in humans due to a product of meperidine analog
28. Neurotoxicity of MPTP and uptake of MPPT into dopamine and norepinephrine neurons in mice
29. Deprenyl in Parkinson's disease
30. Long-term experience with selegiline and levodopa in Parkinson's disease
31. Effect of enantiomers of deprenyl (selegiline) and amphetamine on physical abuse liability and cortical electrical activity in rats
32. A simple quantitative bradykinesia test in MPTP-treated mice
33. Does selegiline monotherapy in Parkinson's disease act by symptomatic or protective mechanisms?
34. Possible mechanism of action of deprenyl in Parkinsonism
35. The effect of monoamine oxidase inhibitors on some arylalkylamines in rat striatum
36. Deprenyl is metabolized to methamphetamine and amphetamine in man
37. The overall rod performance test in the MPTP-treated mouse model of Parkinsonism
38. L-deprenyl treatment of on-off phenomena in Parkinson's disease
39. Quantitative enzyme radioautography with 3H-Ro 41-1049 and 3H-Ro 19-6327 in vitro: Localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs, and human brain
40. Strain-dependent recovery of open-field behavior and striatal dopamine deficiency in the mouse MPTP model of Parkinson's Disease
41. The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice
42. Chronic neurochemical and behavioural changes in MPTP-lesioned C57 BL/6 mice: A model for Parkinson's disease
43. The effect of deprenyl (Selegiline) on the natural history of Parkinson's disease
44. Deprenyl in Parkinson's disease: Mechanisms, neuroprotective effect, indications and adverse effects
45. L-3,4-Dihydroxyphenyl-alanine-induced dopamine release in the striatum of intact and 6-hydroxydopamine-treated rats: Differential effects of monoamine oxidase A and B inhibitors
46. Dopamine receptors and sensorimotor behavior in MPTP-treated mice
47. Histochemical, biochemical and behavioural consequences of MPTP treatment in C-57 black mice
48. Hepatic and extrahepatic metabolism of deprenyl, a selective monoamine oxidase (MAO) B inhibitor, of amphetamines in rats: Sex and strain differences